SEC Form 4 · accession 0001171843-16-013465
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mohammad Azab
Director
Period of report
Dec 1, 2016
Accepted (ET)
Dec 2, 2016 · 6:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Dec 1, 2016 | M | 12,345 | $3.21 | A | 17,283 | D | |
| Common SharesF2,F3 | Dec 1, 2016 | F | 4,408 | $7.80 | D | 12,875 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F4 | $3.21 | Dec 1, 2016 | M | 12,345 | D | — | Dec 31, 2016 | Common Shares | 12,345 | 0 | D |
Explanation of responses
- F1The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person in favor of the underwriters of the Company's Public Offering in September 2016 (the "Lock-up"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up.
- F3Represents the closing price of the Company's common shares in U.S. dollars on November 30, 2016, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- F4The shares subject to the option fully vested on December 31, 2009.